Andrew M. Dahlem, D.V.M. (h.c.), Ph.D., was named vice president and chief operating officer for Lilly Research Laboratories (LRL) and LRL Europe in February 2007. He has previously served as vice president of toxicology, drug disposition, pharmacokinetics, and Lilly Research Laboratories in Europe since January 2003 and is a member of Lilly senior management. Dr. Dahlem received a bachelor of science degree in wildlife biology from The Ohio State University in 1982 and a doctor of philosophy degree in toxicology from the College of Veterinary Medicine at the University of Illinois at Urbana-Champaign in 1989. In 2014 he was awarded a Doctor of Veterinary Medicine Degree (honoris causa) from the College of Veterinary Medicine at Purdue University. Dahlem joined Lilly in 1990 as a senior pharmacologist where he worked on improving the ADME properties of molecules to treat Alzheimer’s Disease and HIV/AIDS. He became head of biochemical toxicology in 1992. He was named director of drug disposition and biochemical (investigative) toxicology in 1993. He was promoted to executive director for toxicology and drug disposition in 1998, and he assumed responsibility for LRL in Europe in 1999 and for discovery operations in 2000. In December 2001 he was promoted to Vice President. Dr. Dahlem serves as adjunct professor of toxicology in the College of Veterinary Medicine at Purdue University, the University of Illinois at Urbana-Champaign, and at The Ohio State University. He is also a member of The Ohio State University College of Pharmacy Corporate Council, the Illinois Professional Science Master’s Board, and the Purdue University’s Discovery Park Advisory Council. He is a member of the Drug Discovery and Development Core of the Institute of Clinical and Translational Research at the University of Iowa and The Ohio State University’s Center for Clinical and Translational Science External Advisory Board. Dr. Dahlem currently serves on the board of directors for Indigo Biosystems and is a member of the Indiana State Museum Foundation Board of Directors. He is a member of the Institute of Medicine Forum on Drug Discovery, Development and Translation and the Translational Research and the Critical Path for Tuberculosis Drug Regimens for the Gates Foundation. He is a member and past president of Indianapolis/Cincinnati Discussion Group of the American Association of Pharmaceutical Scientists.